Walvax Biotechnology Co Ltd
SZSE:300142
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.9
24.78
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Walvax Biotechnology Co Ltd
Long-Term Investments
Walvax Biotechnology Co Ltd
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
W
|
Walvax Biotechnology Co Ltd
SZSE:300142
|
Long-Term Investments
ÂĄ1.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
31%
|
|
Beigene Ltd
HKEX:6160
|
Long-Term Investments
ÂĄ635.2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Long-Term Investments
ÂĄ10m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Long-Term Investments
ÂĄ1.4B
|
CAGR 3-Years
89%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Long-Term Investments
ÂĄ17B
|
CAGR 3-Years
8%
|
CAGR 5-Years
117%
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Long-Term Investments
ÂĄ295.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
24%
|
CAGR 10-Years
39%
|
Walvax Biotechnology Co Ltd
Glance View
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.
See Also
What is Walvax Biotechnology Co Ltd's Long-Term Investments?
Long-Term Investments
1.7B
CNY
Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Long-Term Investments amounts to 1.7B CNY.
What is Walvax Biotechnology Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
31%
Over the last year, the Long-Term Investments growth was 30%. The average annual Long-Term Investments growth rates for Walvax Biotechnology Co Ltd have been -2% over the past three years , 14% over the past five years , and 31% over the past ten years .